NO794295L - Fremgangsmaate til fremstilling av et antibakterielt preparat med forlenget virkningsvarighet - Google Patents
Fremgangsmaate til fremstilling av et antibakterielt preparat med forlenget virkningsvarighetInfo
- Publication number
- NO794295L NO794295L NO794295A NO794295A NO794295L NO 794295 L NO794295 L NO 794295L NO 794295 A NO794295 A NO 794295A NO 794295 A NO794295 A NO 794295A NO 794295 L NO794295 L NO 794295L
- Authority
- NO
- Norway
- Prior art keywords
- penicillanic acid
- methyleneamino
- hexahydro
- pharmaceutically acceptable
- compounds
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 20
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 8
- RBKMMJSQKNKNEV-RITPCOANSA-N penicillanic acid Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2CC(=O)N21 RBKMMJSQKNKNEV-RITPCOANSA-N 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 18
- 229930182555 Penicillin Natural products 0.000 claims description 12
- BWWVAEOLVKTZFQ-NTZNESFSSA-N Amdinocillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=CN1CCCCCC1 BWWVAEOLVKTZFQ-NTZNESFSSA-N 0.000 claims description 11
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 8
- 229940049954 penicillin Drugs 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229960003669 carbenicillin Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 claims description 2
- 229940056360 penicillin g Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 7
- 150000002960 penicillins Chemical class 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000013207 serial dilution Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- -1 acetoxymethyl Chemical group 0.000 description 4
- 229950008796 bacmecillinam Drugs 0.000 description 4
- XHKFBADIZIDYBU-MLFVOLAISA-N chembl2106658 Chemical compound N(/[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OC(C)OC(=O)OCC)=C\N1CCCCCC1 XHKFBADIZIDYBU-MLFVOLAISA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229940024554 amdinocillin Drugs 0.000 description 3
- 229960002699 bacampicillin Drugs 0.000 description 3
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 3
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N chembl530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB5067571A GB1405886A (en) | 1971-11-01 | 1971-11-01 | Synergistic compositions comprising penicillin and cephalosporin antibiotics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO794295L true NO794295L (no) | 1973-05-03 |
Family
ID=10456894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO794295A NO794295L (no) | 1971-11-01 | 1979-12-27 | Fremgangsmaate til fremstilling av et antibakterielt preparat med forlenget virkningsvarighet |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4956179A (enExample) |
| JP (1) | JPS4852917A (enExample) |
| AT (1) | AT324550B (enExample) |
| AU (1) | AU474065B2 (enExample) |
| DE (2) | DE2265533C2 (enExample) |
| FI (1) | FI792124A7 (enExample) |
| FR (1) | FR2158427B1 (enExample) |
| GB (1) | GB1405886A (enExample) |
| NL (1) | NL176525C (enExample) |
| NO (1) | NO794295L (enExample) |
| SE (1) | SE401087B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479838A (en) * | 1974-02-28 | 1977-07-13 | Fujisawa Pharmaceutical Co | Antibacterial composition |
| GB1579931A (en) * | 1976-04-15 | 1980-11-26 | Leo Pharm Prod Ltd | Bis-penicillanoyl-oxy-alkanes |
| US4345071A (en) | 1976-06-29 | 1982-08-17 | Leo Pharmaceutical Products, Ltd. A/S | Derivatives of penicillanic acid |
| LU77362A1 (enExample) * | 1977-05-17 | 1979-01-19 | ||
| JPS542337A (en) * | 1977-06-08 | 1979-01-09 | Toyama Chem Co Ltd | Bactericidal composition for medical use |
| IL54859A (en) * | 1977-06-21 | 1982-01-31 | Rech Applications Therap | Derivatives of amidinopenicillanic acid,their production and pharmaceutical compositions containing them |
| JPS54126735A (en) * | 1978-03-24 | 1979-10-02 | Toyama Chem Co Ltd | Bactericidal composition for medical use |
| NZ194785A (en) * | 1979-09-21 | 1983-05-31 | Leo Pharm Prod Ltd | Double-layer tablet containing penicillanic acid pro-drug in each layer |
| US8366787B2 (en) * | 2000-08-04 | 2013-02-05 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorbable scaffolds |
| US6638312B2 (en) * | 2000-08-04 | 2003-10-28 | Depuy Orthopaedics, Inc. | Reinforced small intestinal submucosa (SIS) |
| JP4197160B2 (ja) * | 2001-07-16 | 2008-12-17 | デピュイ・プロダクツ・インコーポレイテッド | 軟骨修復および再生用の支持骨格材料および方法 |
| EP1416874A4 (en) | 2001-07-16 | 2007-04-18 | Depuy Products Inc | BIOLOGICAL / SYNTHETIC POROUS EXTRACELLULAR HYBRID MATRIX SCUFF |
| US7201917B2 (en) | 2001-07-16 | 2007-04-10 | Depuy Products, Inc. | Porous delivery scaffold and method |
| US7819918B2 (en) * | 2001-07-16 | 2010-10-26 | Depuy Products, Inc. | Implantable tissue repair device |
| US8337537B2 (en) | 2001-07-16 | 2012-12-25 | Depuy Products, Inc. | Device from naturally occurring biologically derived materials |
| US7163563B2 (en) | 2001-07-16 | 2007-01-16 | Depuy Products, Inc. | Unitary surgical device and method |
| AU2002354911B2 (en) | 2001-07-16 | 2007-08-30 | Depuy Products, Inc. | Meniscus regeneration device and method |
| US8025896B2 (en) | 2001-07-16 | 2011-09-27 | Depuy Products, Inc. | Porous extracellular matrix scaffold and method |
| AU2002320517B2 (en) | 2001-07-16 | 2008-03-13 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorable scaffolds |
| US7569233B2 (en) | 2004-05-04 | 2009-08-04 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorbable scaffolds |
| US7513866B2 (en) | 2004-10-29 | 2009-04-07 | Depuy Products, Inc. | Intestine processing device and associated method |
| US7354627B2 (en) | 2004-12-22 | 2008-04-08 | Depuy Products, Inc. | Method for organizing the assembly of collagen fibers and compositions formed therefrom |
| US7595062B2 (en) | 2005-07-28 | 2009-09-29 | Depuy Products, Inc. | Joint resurfacing orthopaedic implant and associated method |
| US20070112360A1 (en) * | 2005-11-15 | 2007-05-17 | Patrick De Deyne | Bioprosthetic device |
| US7871440B2 (en) | 2006-12-11 | 2011-01-18 | Depuy Products, Inc. | Unitary surgical device and method |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1167424A (fr) * | 1952-10-29 | 1958-11-25 | American Home Prod | Procédé de fabrication de compositions de pénicilline |
| GB1272660A (en) * | 1969-12-24 | 1972-05-03 | Beecham Group Ltd | Therapeutic compositions |
| US4221781A (en) * | 1971-11-01 | 1980-09-09 | Astra Lakemedel Aktiebolag | Synergistic penicillin-cephalosporin compositions and methods |
-
1971
- 1971-11-01 GB GB5067571A patent/GB1405886A/en not_active Expired
-
1972
- 1972-10-18 DE DE2265533A patent/DE2265533C2/de not_active Expired
- 1972-10-18 DE DE2250993A patent/DE2250993C2/de not_active Expired
- 1972-10-25 AU AU48126/72A patent/AU474065B2/en not_active Expired
- 1972-10-25 AT AT910172A patent/AT324550B/de not_active IP Right Cessation
- 1972-10-26 NL NLAANVRAGE7214478,A patent/NL176525C/xx not_active IP Right Cessation
- 1972-10-31 SE SE7214083A patent/SE401087B/xx unknown
- 1972-10-31 FR FR7238691A patent/FR2158427B1/fr not_active Expired
- 1972-11-01 JP JP47108956A patent/JPS4852917A/ja active Pending
-
1979
- 1979-07-05 FI FI792124A patent/FI792124A7/fi not_active Application Discontinuation
- 1979-12-27 NO NO794295A patent/NO794295L/no unknown
-
1987
- 1987-07-02 US US07/069,787 patent/US4956179A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2158427A1 (enExample) | 1973-06-15 |
| NL176525C (nl) | 1985-05-01 |
| AU474065B2 (en) | 1976-07-15 |
| FI792124A7 (fi) | 1981-01-01 |
| GB1405886A (en) | 1975-09-10 |
| DE2265533C2 (de) | 1983-12-29 |
| AU4812672A (en) | 1974-04-26 |
| DE2250993C2 (de) | 1982-12-30 |
| FR2158427B1 (enExample) | 1976-07-02 |
| SE401087B (sv) | 1978-04-24 |
| US4956179A (en) | 1990-09-11 |
| JPS4852917A (enExample) | 1973-07-25 |
| AT324550B (de) | 1975-09-10 |
| NL176525B (nl) | 1984-12-03 |
| NL7214478A (enExample) | 1973-05-03 |
| DE2250993A1 (de) | 1973-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO794295L (no) | Fremgangsmaate til fremstilling av et antibakterielt preparat med forlenget virkningsvarighet | |
| KR0149672B1 (ko) | 클로스트리듐 디피실레 하리증 및 위막성 대장염의 예방 및 치료용 의약조성물 | |
| CN103565798B (zh) | 广藿香酮及其衍生物的新用途 | |
| Graessle et al. | The in vitro effect of para-aminosalicylic acid (PAS) in preventing acquired resistance to streptomycin by Mycobacterium tuberculosis | |
| CN110305193B (zh) | 一种抗牙龈卟啉单胞菌多肽及应用 | |
| Waisbren et al. | Comparative action of aureomycin, chloromycetin, neomycin, Q-19, and polymyxin B against gram negative bacilli | |
| CN101003539A (zh) | 西林类化合物的氨丁三醇盐及其制备方法 | |
| CN101336903B (zh) | 注射用左旋奥硝唑磷酸二钠静脉制剂的制备方法 | |
| RU2000799C1 (ru) | Стимул тор иммунологической резистентности организма | |
| CN114522169B (zh) | 一种治疗幽门螺杆菌中药单体组合物及其制备方法和应用 | |
| CN113384586B (zh) | 原花青素黄酮类中药单体在协同增效头孢噻呋钠抗mrsa耐药菌作用的用途 | |
| CN113209085B (zh) | 水鬼蕉新碱a在制备抗菌药物中的应用 | |
| CN108434438A (zh) | 抗菌肽在制备治疗幽门螺杆菌病的药物中的用途以及药物组合物 | |
| CN114869871A (zh) | 紫檀茋在抗水产养殖动物嗜水气单胞菌感染中的应用 | |
| Rachma et al. | Secondary metabolite of Aspergillus oryzae impairs cell envelope integrity Klebsiella pneumoniae producing extended-spectrum beta-lactamase | |
| Nutini et al. | Comparative Action of an Extract of Brain Tissue and Penicillin on Staphylococcus aureus Infections | |
| US10159708B2 (en) | Method for the treatment of acne | |
| Davis et al. | URINARY ANTISEPSIS THE SECRETION OF ANTI-SEPTIC URINE FOLLOWING THE INTRAVENOUS ADMINISTRATION OF ACRIFLAVINE OF ACRIFLAVINE AND PRO-FLAVINE-PRELIMINARY REPORT | |
| CN100352915C (zh) | 一种枯草芽孢杆菌，其复合制剂及该复合制剂的制备方法 | |
| CN102462686A (zh) | 一种用于防治畜禽大肠杆菌病的药物组合物 | |
| CN112755024A (zh) | 一种青霉素增效减量联合抑菌剂及其制备方法 | |
| Stafford | Penicillin | |
| CN117959299A (zh) | 一种异白叶藤碱衍生物在防治奶牛乳腺炎致病菌中的用途 | |
| NO750788L (enExample) | ||
| CN116747225A (zh) | 一种小檗碱衍生物在防治奶牛乳腺炎致病菌中的用途 |